6-(1-methylhydrazino)isocytosine | 67873-21-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-(1-methylhydrazino)isocytosine
• 英文别名: 6-(1-Methylhydrazino)isocytosine hemihydrate；2-Amino-4-<1-methyl-hydrazino>-6(1H)-pyrimidon；6-(1-Methylhydrazino)isocytosin；2-amino-6-(1-methylhydrazinyl)pyrimidin-4(3H)-one；2-amino-6-(N-methyl-hydrazino)-3H-pyrimidin-4-one；6-(1-methylhydrazinyl)-2-aminopyrimidin-4(1H)-one；2-amino-4-[amino(methyl)amino]-1H-pyrimidin-6-one
• CAS: 67873-21-6
• 化学式: C₅H₉N₅O
• 分子量: 155.159
• InChiKey: AESGJYVQDCJVQY-UHFFFAOYSA-N

物化性质

• 熔点：
  274-280 °C
• 沸点：
  323.1±52.0 °C(Predicted)
• 密度：
  1.63±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  96.7
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(1-methylhydrazino)isocytosine 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 239.0h， 生成 6-amino-1-methyl-3-phenyl-1H-pyrazolo<3,4-d>pyrimidin-4(5H)-one
  参考文献：
  名称：

  Pyrimido[4,5-c]pyridazines. 3. Preferential formation of 8-amino-1H-pyrimido[4,5-c]-1,2-diazepin-6(7H)-ones by cyclizations with .alpha.,.gamma.-dioxo esters

  摘要：

  DOI：

  10.1021/jo00343a013
• 作为产物：
  描述：

  2-氨基-6-氯-4-羟基嘧啶 、 甲基肼 以 水 为溶剂， 反应 3.0h， 以74%的产率得到6-(1-methylhydrazino)isocytosine
  参考文献：
  名称：

  基于结构的新型嘧啶并[4,5-c]哒嗪衍生物作为具有增加亲和力的二氢蝶酸合酶抑制剂的设计

  摘要：

  二氢蝶酸合酶 (DHPS) 是磺胺类抗菌治疗的有效药物靶点。然而，由于普遍存在耐药性和耐受性差，目前磺胺类抗生素的使用受到限制。DHPS 中的蝶呤结合口袋高度保守，与磺胺结合位点不同。因此，它代表了设计新型抗菌剂的有吸引力的替代目标。我们之前在炭疽芽孢杆菌顺式 DHPS 蝶呤位点中对已知哒嗪抑制剂进行了结构表征，并确定了许多不利的相互作用，这些相互作用似乎会损害结合。有了这些结构信息，一系列 4,5-dioxo-1,4,5,6-tetrahydropyrimido[4,5- c]哒嗪旨在提高结合亲和力。最重要的是，去除了N-甲基环取代以改善蝶呤口袋内的结合，并且优化了侧链羧酸的长度以完全接合焦磷酸结合位点。这些抑制剂是通过酶活性测定、X 射线晶体学、等温量热法和表面等离子体共振合成和评估的，以从结构、动力学和热力学角度全面了解结合相互作用。该研究清楚地表明，缺乏N-甲基取代的化合物对 DHPS

  DOI：

  10.1002/cmdc.201200049

文献信息

• Substituted pyrimido (4,5-c)pyridazines
  申请人：Burroughs Wellcome Co.

  公开号：US04255427A1

  公开（公告）日：1981-03-10

  This invention provides pyrimido (4,5-c)pyridazines, process for their preparation, veterinary compositions containing them and the preparation of such compositions. These pyrimido (4,5-c)pyridazines are useful in the treatment of coccidiosis.

  这项发明提供了嘧啶并[4,5-c]吡啶嗪，其制备方法，含有它们的兽药组合物以及这种组合物的制备。这些嘧啶并[4,5-c]吡啶嗪在球虫病的治疗中很有用。
• Pyrimido(4,5-c)pyridazines
  申请人：Burroughs Wellcome Co.

  公开号：US04225710A1

  公开（公告）日：1980-09-30

  The present invention provides pyrimido(4,5-c)pyridazines, to methods for preparing them, formulations containing them and the preparation of such formulation and the use of such compounds in human therapy. These pyrimido(4,5-c)pyridazines of this invention are useful due to their activity as inhibitors of dihydropteroic and biosynthesis.

  本发明提供了嘧啶并[4,5-c]吡啶嗪，以及制备它们的方法、含有它们的配方和该配方的制备以及这些化合物在人类治疗中的应用。本发明的这些嘧啶并[4,5-c]吡啶嗪因其作为二氢叶酸和生物合成抑制剂的活性而具有用处。
• Fully Supramolecular Chiral Hydrogen-Bonded Molecular Tweezer
  作者：Augustina Jozeliu̅naitė、Tomas Javorskis、Vytenis Vaitkevičius、Vytautas Klimavičius、Edvinas Orentas

  DOI：10.1021/jacs.2c01455

  日期：2022.5.11

  molecular architectures with high potential for various applications in supramolecular chemistry. Their covalent synthesis, however, is often tedious and the structures obtained lack structural responsiveness beyond the limited conformational flexibility of the scaffold. Herein we present a proof-of-concept study on the design, synthesis, assembly, and transformations of a novel supramolecular construct─a

  分子镊子是开放式、具有空腔的 U 形分子结构，在超分子化学的各种应用中具有很高的潜力。然而，它们的共价合成通常是乏味的，并且获得的结构缺乏结构响应性，超出了支架有限的构象灵活性。在此，我们对一种新型超分子结构（一种完全非共价分子镊子）的设计、合成、组装和转化进行了概念验证研究。超分子镊子由一组四个构件组装而成，由两个相同的分子角条和两个扁平的芳香延伸翼组成，仅使用氢键。手性辅助聚集过程用于使用对映体纯双环角棒确保支架弯曲方向性。为了解决与平衡从循环聚集体中自互补角条的强合作自恋自分类向分子镊子中的综合自分类转变相关的挑战，应用了合理的去对称化策略。动态超分子镊子已显示出丰富的超分子化学，允许聚合拓扑结构的刺激响应变化和溶剂响应超分子聚合。
• Toxoflavins and Deazaflavins as the First Reported Selective Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase II
  作者：Ali Raoof、Paul Depledge、Niall M. Hamilton、Nicola S. Hamilton、James R. Hitchin、Gemma V. Hopkins、Allan M. Jordan、Laura A. Maguire、Alison E. McGonagle、Daniel P. Mould、Mathew Rushbrooke、Helen F. Small、Kate M. Smith、Graeme J. Thomson、Fabrice Turlais、Ian D. Waddell、Bohdan Waszkowycz、Amanda J. Watson、Donald J. Ogilvie

  DOI：10.1021/jm400568p

  日期：2013.8.22

  The recently discovered enzyme tyrosyl-DNA phosphodiesterase 2 (TDP2) has been implicated in the topoisomerase-mediated repair of DNA damage. In the clinical setting, it has been hypothesized that TDP2 may mediate drug resistance to topoisomerase II (topo II) inhibition by etoposide. Therefore, selective pharmacological inhibition of TDP2 is proposed as a novel approach to overcome intrinsic or acquired resistance to topo II-targeted drug therapy. Following a high-throughput screening (HTS) campaign, toxoflavins and deazaflavins were identified as the first reported sub-micromolar and selective inhibitors of this enzyme. Toxoflavin derivatives appeared to exhibit a clear structure-activity relationship (SAP.) for TDP2 enzymatic inhibition. However, we observed a key redox liability of this series, and this, alongside early in vitro drug metabolism and pharmacokinetics (DMPK) issues, precluded further exploration. The deazaflavins were developed from a singleton HTS hit. This series showed distinct SAR and did not display redox activity; however low cell permeability proved to be a challenge.
• Pyrimido[4,5-c]pyridazines. 5. Summary of cyclizations with vicinally functionalized reagents and studies of the reductive behavior of the ring system
  作者：Robert W. Morrison、Virgil L. Styles

  DOI：10.1021/jo00343a014

  日期：1982.2